PTX 001
Alternative Names: Beta-pep 25; PTX001Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator University of Minnesota
- Developer PepTx; University Hospital Maastricht
- Class Antineoplastics; Peptide antibiotics
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Netherlands (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 25 Mar 2008 Preclinical development is ongoing